197 related articles for article (PubMed ID: 34496797)
1. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
Zang C; Zhao Y; Qin L; Liu G; Sun J; Li K; Zhao Y; Sheng S; Zhang H; He N; Zhao P; Wang Q; Li X; Peng Y; Dong T; Zhang Y
BMC Cancer; 2021 Sep; 21(1):1007. PubMed ID: 34496797
[TBL] [Abstract][Full Text] [Related]
2. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.
Hiroishi K; Eguchi J; Baba T; Shimazaki T; Ishii S; Hiraide A; Sakaki M; Doi H; Uozumi S; Omori R; Matsumura T; Yanagawa T; Ito T; Imawari M
J Gastroenterol; 2010 Apr; 45(4):451-8. PubMed ID: 19936602
[TBL] [Abstract][Full Text] [Related]
3. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
Flecken T; Schmidt N; Hild S; Gostick E; Drognitz O; Zeiser R; Schemmer P; Bruns H; Eiermann T; Price DA; Blum HE; Neumann-Haefelin C; Thimme R
Hepatology; 2014 Apr; 59(4):1415-26. PubMed ID: 24002931
[TBL] [Abstract][Full Text] [Related]
4. Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma.
Wang M; Li J; Wang L; Chen X; Zhang Z; Yue D; Ping Y; Shi X; Huang L; Zhang T; Yang L; Zhao Y; Ma X; Li D; Fan Z; Zhao L; Tang Z; Zhai W; Zhang B; Zhang Y
Int J Clin Exp Pathol; 2015; 8(4):3513-28. PubMed ID: 26097535
[TBL] [Abstract][Full Text] [Related]
5. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
7. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.
Sideras K; Bots SJ; Biermann K; Sprengers D; Polak WG; IJzermans JN; de Man RA; Pan Q; Sleijfer S; Bruno MJ; Kwekkeboom J
Br J Cancer; 2015 Jun; 112(12):1911-20. PubMed ID: 26057582
[TBL] [Abstract][Full Text] [Related]
8. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.
Behboudi S; Alisa A; Boswell S; Anastassiou J; Pathan AA; Williams R
Br J Cancer; 2010 Feb; 102(4):748-53. PubMed ID: 20087354
[TBL] [Abstract][Full Text] [Related]
9. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Bricard G; Bouzourene H; Martinet O; Rimoldi D; Halkic N; Gillet M; Chaubert P; Macdonald HR; Romero P; Cerottini JC; Speiser DE
J Immunol; 2005 Feb; 174(3):1709-16. PubMed ID: 15661935
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
11. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
14. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
Fatourou EM; Koskinas JS
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1499-510. PubMed ID: 19828011
[TBL] [Abstract][Full Text] [Related]
15. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.
Kim SH; Lee S; Lee CH; Lee MK; Kim YD; Shin DH; Choi KU; Kim JY; Park DY; Sol MY
Lung; 2009; 187(6):401-11. PubMed ID: 19795170
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
17. Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients.
Noordam L; de Beijer MTA; Mancham S; Vogler I; Boor PPC; de Ruiter V; Luijten R; IJzermans JNM; Sahin U; Bruno MJ; Sprengers D; Buschow SI; Kwekkeboom J
Oncoimmunology; 2022; 11(1):2131096. PubMed ID: 36211805
[TBL] [Abstract][Full Text] [Related]
18. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
[TBL] [Abstract][Full Text] [Related]
19. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
Schmidt N; Neumann-Haefelin C; Thimme R
Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
[TBL] [Abstract][Full Text] [Related]
20. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients.
Guan HT; Wang J; Yang M; Song L; Tong XQ; Zou YH
Chin Med J (Engl); 2013; 126(19):3651-5. PubMed ID: 24112158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]